ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,712.69
-0.28%
US Tech 100
19,429.60
-0.35%
Dow Jones
41,794.60
-0.61%
Brent Oil
75.28
1.63%
Bitcoin
67,411.14
-1.94%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) News

argenx SE

argenx SE (ARGX)

Argen X SE
587.80
-7.78
( -1.31% )
Updated: 15:58:47
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

ARGX News

Official News Only

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 31 2024
ARGX (-1.31%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 15 2024
ARGX (-1.31%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
September 19 2024
ARGX (-1.31%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
July 25 2024
ARGX (-1.31%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
July 16 2024
ARGX (-1.31%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
July 16 2024
ARGX (-1.31%)

ARGX Discussion

View Posts
Monksdream Monksdream 1 day ago
ARGX new 52+week high
👍️0
Monksdream Monksdream 2 months ago
ARGX over $500

👍️0
Monksdream Monksdream 3 months ago
ARGX new 52 week high
👍️0
Monksdream Monksdream 3 months ago
ARGX under $500
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 4 years ago
Looking good
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 4 years ago
Progress in Sub-cu Efgartigimod was discussed in some detail yesterday during the Halozyme conference call.
👍️0
jonny_red jonny_red 5 years ago
3 Penny Stocks To Buy Or Sell Before Friday? 1 Up 110% This Quarter

$CLSD $AR $AGRX

https://www.transparenttraders.me/2019/11/3-penny-stocks-to-buy-or-sell-before.html
👍️0
ClayTrader ClayTrader 6 years ago
* * $AGRX Video Chart 11-01-18 * *

Link to Video - click here to watch the technical chart video

👍️0
riche riche 6 years ago
Efgartigimod is a first-in-class antibody fragment designed for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G, or IgG, antibodies for which few innovative biologic treatments have been approved and severe unmet medical need exists. Efgartigimod has been created to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications: multiple sclerosis, immune thrombocytopenia, systemic lupus erythematosus, myasthenia gravis and skin blistering

👍️0
riche riche 6 years ago
Year targets !!

KBC 87 euro Wedbush 121 $ = 104 euro Piper Jaffray 154 $ = 132 euro JMP Securities 150 $ = 129 euro Stiffel 139 $ = 119,50 euro Nomura 161 $ = 138,40 Kempen en Co 140 euro

STRONG BUY !!!
👍️0
riche riche 6 years ago
1-4 Dec 2018: Efgartigimod full Phase II ITP data, ARGX-110 full Phase I AML dose-escalation data, ARGX-110 full Phase II CTCL data YE 2018: launch of Phase III MG trial with Efgartigimod.

👍️0
riche riche 6 years ago
https://thefly.com/landingPageNews.php?id=2794139 Argenx data concerns over rescue therapy unfounded, says Piper Jaffray Argenx last week reported positive Phase II immune thrombocytopenia data on efgartigimod showing clean safety and clear efficacy, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. He points out that twelve, or 46%, efgartigimod-treated patients achieved clinically meaningful platelet improvement. The analyst views concern over rescue therapy and bleeding events as unfounded and reiterates an Overweight rating on Argenx shares with a $154 price target. Bioscience liked last!Lampi, Bioscience waardeerde(-n)

👍️0
riche riche 6 years ago
Sorry, theWhat a JOKE!...SOLD 3.5M shares at $86.50 a share...BUT...also gave each share an option to buy a share at equivalent of $ .15 a share.... therefore 7MM shares at equivalent $43.25 a share...THIS IS GOING DOWN!!! "closing of its public offering in the United States and an offering in Europe only to qualified investors (within the meaning of Directive 2003/71/EC, as amended) (the Offering) of 3,475,000 American Depositary Shares (ADSs) at a price to the public of $86.50 per ADS, for gross proceeds of approximately $300.6 million, before deducting underwriting discounts and commissions and offering expenses payable by argenx.Each of the ADSs offered represents the right to receive one ordinary share, nominal value of #$%$0.10 per share. All of the ADSs in the Offering were offered by argenx." Ik heb de vraag gisterenavond voor gelegd bij ARgen-X Hieronder het bericht zoals het uitgelegd moet worden . Gegeven door niet minder dan Joke Comijn dir . IR ARgenx Dag Bioscience De nominale waarde is de waarde van het aandeel zoals die staat beschreven in de statuten van een NV. De nominale waarde heeft niets te maken met de werkelijke waarde van een aandeel, en ook niet met de discount van de transactie. Dit is duidelijk te zien op de balans van de meeste (beursgenoteerde) bedrijven waar je onder de equity zowel share capital (de nominale waarde van alle aandelen) als share premium (de betaalde waarde voor de aandelen bovenop de nominale waarde) terugvindt. https://nl.wikipedia.org/wiki/Nominale_waarde Bijkomend wil ik nog laten weten dat de inschrijvers op ADSen geen recht hebben op een ‘bijkomend’ aandeel: bij de kapitaalverhoging zijn de aandelen gecreëerd, die vervolgens in bewaring zijn gegeven, die op haar beurt per in bewaring gegeven aandeel een certificaat (American Depository Security) heeft uitgegeven aan de aandeelhouders die hun argenx aandelen op Nasdaq verhandelen. De reden hiervoor is dat er juridische belemmeringen zijn om aandelen van een Nederlandse vennootschap rechtstreeks op Nasdaq te verhandelen. Met vriendelijke groeten, Joke DUS de aandelen zijn gekocht voor $ 86,50 en niet voor minder !!! ( geen extra korting . Daar zitten we nu dus al 11 $ onder .

Lees meer op: https://beursig.com/forum/viewtopic.php?f=4&t=1804&start=2050 voor meer informatie answer is in Dutch.
👍️0
riche riche 6 years ago
https://clinicaltrials.gov/ct2/show/NCT03102593
👍️0
Justfactsmam Justfactsmam 6 years ago
I don't think so...TOXIC FINANCING DEAL ....EU private financing deal...just gave away 7MM share at $43.50 a share when was trading over double that last week...

3.5 MM shares sold at $86.50 a share...BUT...also gave each share an option to buy a share at equivalent of $ .15 a share.... therefore 7MM shares at equivalent $43.25 a share...

THIS IS GOING DOWN!!!
👍️0
stocktrademan stocktrademan 7 years ago
ARGX buy 75.10



















normal chart




log chart



👍️0

Your Recent History

NASDAQ
ARGX
argenx
AQSE
TPT.GB
Topps Tiles
AMEX
AST
Asterias Biotherapeutics, Inc.
BIT
1STZ
Constellation Brands
LSE
FS14
Mitsu Hc Cap.26
NYSE
DNK
Phoenix Tree
LSE
RCG
RCG
LSE
BG.
BG Group
NASDAQ
LMAT
LeMaitre Vascular
TSX
ZMID
BMO S & P US Mid Cap Ind...
LSE
TIK
Tikit
NYSE
MIXT
MiX Telematics
BMF
WDOZ24
WDOZ24 - Dezembro 2024
BOV
EMAE4
EMAE PN
NASDAQ
FCFP
First Community Financial
USOTC
ERBB
American Green (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved